Affiliations: Department of Urology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Correspondence:
[*]
Corresponding author: Yu-Jie Wang, Department of Urology, the First Affiliated Hospital of Xinjiang Medical University,
Urumqi, Xinjiang, China. E-mail: [email protected]
Abstract:
BACKGROUND AND OBJECTIVE: Looking for tumor markers by
using protein chip technology is one of the hot topics, but many studies are
still limited on short term detection of differential expressed proteins
before and after surgery among patients with RCC. This study analyzed
differential expressed serum protein and its clinical significance with
clear-cell renal cell carcinoma to further measurement of the rule of
variable expressing. METHODS: Eighty-nine patients with clear-cell renal cell
carcinoma who underwent surgery from November 2013 to 2014 and
postoperatively confirmed by pathology were entered in RCC group, 100
healthy volunteers and patients without RCC who underwent medical
examination in the same period were entered in control group. The serum
protein were analyzed in both group before surgery and every regular
follow-up period in 1 year after surgery with RCC group. The
surface-enhanced laser desorption ionization time of flight mass
spectrometry (SELDI-TOF-MS) and weak cation exchange protein chip (CM10)
technology systems were used for identifying differential expressed serum
protein in RCC group and controls. The linear support vector machine
(SVM) was applied to establish the diagnostic model of protein fingerprints
and the leave-one-out cross validation was used for determining model
discriminating effect. The differential expressed proteins were
analyzed by ZUCI-PDAS protein spectral data analysis system. RESULTS: Five kinds of proteins were identified as potential biomarker,
ultimately. The M/Z of these proteins was
15953, 7987, 9304, 8948, 5911, respectively. There were significant difference on
expression level of these proteins with two groups
preoperatively (P< 0.05). Comparison of all postoperative expression levels
to preoperative one and each differential level mutually between a year in
postoperative period also revealed statistical significance (P< 0.05). With
taking identified proteins as biomarker, the sensitivity and specificity in
predicting clear-cell renal cell carcinoma was 88.8% (79/89) and
91.0% (91/100), respectively. CONCLUSION: The corresponding
specific protein was Bcl-2 family apoptosis regulatory proteins, WAP
four-disulfide core protein, Krueppel-like factor 8, monocyte chemotactic
protein-1, serum amyloid β -protein-4, respectively, and will may serve
as tumor markers of kidney cancer. These proteins manifests high predictive
value for clear-cell renal cell carcinoma, and may contribute to therapeutic
evaluation, prognosis and targeted therapy for clear-cell renal cell
carcinoma.
